Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 44.48 million compared to USD 25.19 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.44 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
70.36 USD | +0.11% | +6.33% | -4.58% |
May. 17 | Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing | MT |
May. 16 | Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.58% | 4.54B | |
+49.71% | 55.7B | |
+39.04% | 39.91B | |
-6.55% | 39.57B | |
-6.65% | 28.16B | |
+13.18% | 26.3B | |
-21.89% | 18.94B | |
+29.58% | 12.17B | |
+24.88% | 12.12B | |
-0.49% | 12.12B |
- Stock Market
- Equities
- NUVL Stock
- News Nuvalent, Inc.
- Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024